• Trevor Hawkins, PhD, will joinMDS(Toronto) in the newly created post of chief science and technology officer on May 2. Hawkins most recently served as president of the Molecular Diagnostics business unit at GE Healthcare, where he oversaw GE Healthcare’s move into molecular diagnostics as part of its personalized medicine initiatives. MDS provides enabling products and services to the global health and life sciences industries.

• Patricia Bolden, RN, and Christine Fernandez, RN, have been appointed vice presidents and co-regional directors of the new apheresis operations of PhereSys Therapeutics (El Dorado Hills, California), in Chicago and Minneapolis. PhereSys said that the opening of the Midwest region is part of its plan to build a comprehensive, contract mobile therapeutic apheresis (TA) network. Golden previously was corporate director of TA at Kidney Disease and Critical Care Associates serving the Minneapolis and St. Paul areas. Currently, Golden is president of the American Society of Apheresis, which trains apheresis practitioners. Fernandez formerly was the national director of operations for therapeutic apheresis with Fresenius Medical Care Extracorporeal Alliance. PhereSys Therapeutics provides services to hospitals and physician offices in California and New York.